PRL and prostate cancer: In addition, in the KEGG pathway analysis, 155 KEGG pathways were selected (P-adjust < 0.05) related to all predicted targets, including the drug metabolism-cytochrome P450, metabolism of xenobiotics by cytochrome P450, prolactin signaling pathway, chemical carcinogenesis, platinum drug resistance, prostate cancer, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, adherens junctions, PPAR signaling pathway, fluid shear stress and atherosclerosis, arachidonic acid metabolism, adipocytokine signaling pathway, and tyrosine metabolism (Figure 2H).